Entering a bullish period after a fake out breakdown overreaction after the FOMC last week. What to watch this summer and what is setting up for a run now.
With this stock out of favor yet showing some stable base building, investors are ignoring major catalyst occurring before month end.
Biogen’s new Alzheimer’s, drug approval has investors pondering whether this is enough of a change in mindset to reshape opinions about gene editing companies. Bets are being placed in the options market.
CBR blacklists Interactive Brokers and Exante and 1800+ other companies. Emerging Markets perform well. Our stock picks and Investment Strategies show strength. New trade ideas are presented also.
We see option activity picking up in our favorite Latin American payment service company. Morgan Stanley analysts expect stronger than expected growth. The chart looks interesting for the stock to run again.
Tesla, the best innovator with first mover advantage in EV space, gets all the attention. It has a lofty multiple while other auto makers were shunned. Recently, new products signal a change.
JPMorgan makes the case for an early stage growth opportunity within an established company: Urban Air Travel.
Animal Health companies are showing strength recently. Four stocks are poised for new highs as demand for products remain elevated, according to Credit Suisse.
A buying opportunity in a medtech company arises as a competitor product pulls out.
SPX gets extremely overbought. Our Core Strategy catches up. A breakout in RUTH is possible.